179 results about "Morpholino" patented technology

The present invention provides an improved method for reducing the risk or severity of restenosis following cardiac angioplasty. The method includes administering to a target vessel region, a morpholino antisense compound having uncharged phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA. Also disclosed are novel antisense compounds and compositions, and a method for assaying the effectiveness of antisense delivery and uptake to a target vessel region.

The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components:

wherein X represents nitrogen atom or CH; R₁ represents CH_nF_3-n (wherein n is 1 or 2), hydroxy C₁–C₆ alkyl, NHR₆ [wherein R₆ represents hydrogen atom or COR (wherein R represents hydrogen atom, C₁–C₆ alkyl or C₁–C₆ alkoxy)]; R₂ represents morpholino (which may be substituted with one to four C₁–C₆ alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C₁–C₆ alkyl), oxazolidinyl (which may be substituted with one or two C₁–C₆ alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R₃ and R₄ each represent hydrogen atom or C₁–C₆ alkyl; and R₅ represents hydrogen atom, amino or hydroxyl.

The present invention provides an improved method for reducing the risk or severity of restenosis following cardiac angioplasty. The method includes administering to a target vessel region, a morpholino antisense compound having a phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA. Also disclosed are novel antisense compounds and compositions, and a method for assaying the effectiveness of antisense delivery and uptake to a target vessel region.

Morpholino-based oligomers suitable as antisense agent comprising modifications of phosphorodiamidate backbone or modification with 5-substituted pyrimidines of morpholino compound that is soluble in culture medium and sufficient for cell penetration thereby eliminating the need for injecting into the cells. Monomers comprising the said oligomers and its method of manufacture, method of manufacture of the said oligomers and its dye, flurophore, drug, biomolecule conjugate wherein the said oligomers find different end use but not limited to regulation of gene expression, tissue culture with improved transfection efficiency and related studies on cellular transfection.

The invention is directed to a method of administering hydrogen sulfide (H₂S) slowly and sustainably to an individual in need thereof comprising administering an effective amount of a compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof.

The invention relates to a high-purity (2 beta, 3 alpha, 5 alpha, 16 beta, 17 beta)-2-(4- morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol or a composition thereof, a preparation method thereof (a compound shown in a formula III) or a composition thereof and application thereof to preparing rocuronium (a compound shown in a formula I). The method has good effect, low cost, high quality and simple and convenient operation and is suitable for large-scale industrial production; and the obtained product has high purity and stable properties.

A family of slurries useful in modifying exposed surfaces of wafers for semiconductor fabrication are provided along with methods of modifying exposed surfaces of wafers for semiconductor fabrication utilizing such a family of working slurries, and semiconductor wafers. The slurries of the invention are a solution of initial components, the components comprising: a sulfonated zwitterion selected from 2-(N-Morpholino)ethanesulfonic acid, (3-[N-Morpholino])propanesulfonic acid, 2-[(2-Amino-2-oxoethyl)amino]ethanesulfonic acid, Piperazine-N, N′-bis(2-ethanesulfonic acid), 3-(N-Morpholino)-2-hydroxypropanesulfonic acid, N ,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid, 3-(N-Morpholino)propanesulfonic acid, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid), N-Tris(hydroxymethyl)methyl-2 aminoethanesulfonic acid, 3-[N ,N-Bis(2-hydroxyethyl)amino]-2-hydroxypropanesulfonic acid, 3-[N -Tris(hydroxymethyl)methylamino)-2-hydroxypropanesulfonic acid, N-(2-hydroxyethyl)piperazine-N′-(2-hydroxypropanesulfonic acid), Piperazine-N ,N′-bis(2-hydroxypropanesulfonic acid), N-(2-Hydroxyethyl)piperazine-N′-(3-propanesulfonic acid), N-Tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid, 3-[(1,1-Dimethy 1-2-hydroxyethyl)amino]-2-hydroxypropanesulfonic, acid, 2-(N-Cyclohexylamino)ethanesulfonic acid, 3-(Cyclohexylamino)-2-hydroxy-I-propanesulfonic acid, 2-Amino-2-methyl-I-propanol, 3-(Cyclohexylamino)-1-propanesulfonic acid, an oxidizing agent; optionally, a passivating agent; optionally a chelating agent, optionally abrasive particles, optionally a surfactant, optionally a secondary buffering agent and water. The method of the invention comprises the steps of: a) providing a wafer comprising a first material having a surface etched to form a pattern and a second material deposited over the surface of the first material; b) contacting the second material of the wafer with abrasive in the presence of the working slurry; and c) relatively moving the wafer or polishing pad or both while the second material is in contact with the slurry and abrasive particles until an exposed surface of the wafer is planar and comprises at least one area of exposed first material and one area of exposed second material.

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

The invention relates to a clenbuterol immunomagnetic bead separation and enrichment kit. The clenbuterol immunomagnetic bead separation and enrichment kit comprises a magnetic bead which is coupled to a clenbuterol monoclonal antibody, reconstitution fluid and a magnet, wherein the magnetic bead which is coupled to the clenbuterol monoclonal antibody is formed by mixing and dissolving the clenbuterol monoclonal antibody and the magnetic bead in 2-(N-morpholino) ethanesulfonic acid monohydrate in a coupling way according to a mass ratio of 1:(500 to 1000); the clenbuterol monoclonal antibody is obtained by taking a coupling substance obtained from clenbuterol haptin and bovine serum albumin as an immunogen to immune Balb/c mice; the clenbuterol haptin is obtained by carrying out diazo-reaction on clenbuterol and P-hydroxybenzene propanoic acid and bringing a carboxyl spacer arm on amino. The invention also relates to a sample preprocessing method for separating the clenbuterol by adopting the clenbuterol immunomagnetic bead separation and enrichment kit. According to the sample preprocessing method disclosed by the invention, higher specificity, higher recovery rate and higher accuracy on the clenbuterol are obtained, sample preprocessing steps are simplified, and various and a mass of organic solvents can be prevented from being used during a sample preprocessing procedure.

A method and compound for enhancing the lethality of an anti-cancer therapy, such as radiation, chemotherapy, or TRAIL protein, are disclosed. The compound is composed of morpholino subunits joined by phosphorodiamidate linkages, and has a targeting sequence that is complementary to an AUG start, IRES, or splice-donor region of the transcript for human X-linked inhibitor of apoptosis protein (XIAP). The method includes exposing cancer cells to the compound.

The present invention is directed to oligonucleotides based on peptide nucleic acid oligonucleotide or an equivalent oligonucleotide analogue, such as morpholino or a locked nucleic acid sequences and the use of such oligonucleotides for the dissociation of higher order structures, including triplex-helix DNA structures, in repeated sequences of DNA in Friedreich's ataxia. The dissociation of such structures may be used in the diagnosis and/or treatment of Friedreich's ataxia. Consequently, the present invention is also directed to a method for diagnosing Friedreich's ataxia and the use of peptide nucleic acid oligonucleotide or an equivalent oligonucleotide analogue, such as morpholino or a locked nucleic acid sequences in the treatment of Friedreich's ataxia. Preferably, the oligonucleotides comprise a sequence selected from the group consisting of (GAA)_n, (CTT)_n, (JTT)_n or a mixed (JTT/CTT)_n sequence.

The invention relates to an industrial preparation method of mule (benzo (e) (1,3) oxazine-2, 4'-piperidine)-4(3H)-ketonic, which uses economical, easily-obtained and scale-produced salicylic acid (and various para-orientation salicylic acids) and N-protecting piperidone (including Boc, Cbz, acyl groups and alkyl group protection) as raw materials, and mule (benzo (e) (1,3) oxazine-2, 4'-piperidine)-4(3H)-ketonic is obtained after methyl esterification, aminolysis and the close under the catalysis of piperidine or morpholino. The invention solves the problems of complex reaction, low purity and yield, and the like in the prior art, does not need column chromatography purification and can realize scale industrial production.

This invention relates to the use of one or more RNA target protectors to inhibit the binding of an RNA, e.g., small RNA, to a target RNA (e.g., a target mRNA), thus increasing the stability of the target RNA and its function (e.g., increasing the gene expression of the gene corresponding to a target mRNA). An RNA target protector may be, for example, an oligonucleotide, e.g., a morpholino, or a small molecule. The invention further relates to the treatment of a human patient in need thereof with one or more RNA target protectors.